| Literature DB >> 33635331 |
Akhil Rajendra1, Hasmukh Jain2, V N Avinash Bonda2, Lingaraj Nayak2, Prashant Tembhare3, Dhanlaxmi Shetty4, Jayashree Thorat2, Hemani Jain4, Papagudi Ganesan Subramanian3, Nikhil Patkar3, Gaurav Chatterjee3, Navin Khattry2,5, Anant Gokarn2,5, Sachin Punatar2,5, Smruti Mokal6, Bhausaheb Bagal2, Manju Sengar2.
Abstract
The use of pediatrics-inspired protocols in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) results in superior survival compared with the adult protocols. Pediatrics-inspired protocols carry an increased risk of toxicity and treatment-related mortality in low resource settings, which can offset the potential benefits. We studied the outcomes and prognostic factors in the treatment of AYA ALL with a pediatrics-inspired regimen. We retrieved data regarding demographics, investigations, treatment details, and toxicities from the electronic medical records of patients diagnosed with ALL in the 15- to 25-year-old age group who were initiated on a modified Berlin-Frankfurt-Münster 90 (BFM-90) protocol between January 2013 and December 2016 at the Tata Memorial Centre. A total of 349 patients in the 15- to 25-year-old age group were treated with a modified BFM-90 protocol. The use of this pediatrics-inspired protocol resulted in a 3-year event-free survival (EFS) and overall survival (OS) of 59.4% and 61.8%, respectively. Only 15 patients underwent an allogeneic stem cell transplant. Minimal residual disease (MRD) persistence postinduction emerged as the only factor predictive of poor outcomes. A modified BFM-90 protocol is an effective and safe regimen for AYA ALL with an OS and EFS comparable to the published literature.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33635331 PMCID： PMC7948264 DOI： 10.1182/bloodadvances.2020003526
Source DB: PubMed Journal: Blood Adv ISSN： 2473-9529